الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 195 |  |  |
| | | from | 195 | | |
Abstract
The main aim of the study is to evaluate the effect metformin on metastatic breast cancer when added to standard chemotherapy and association between the addition of metformin to the radiological response in metastatic breast cancer as well as overall survival (OS) and progression free survival (PFS), also if metformin affects insulin growth like factor IGF-1 in patient with metastatic breast cancer and the association between IGF-1 and radiological response.
50 patients of metastatic breast cancer were randomized to 25 in metformin group and 25 in control group. Patients in metformin group started to take metformin 1 gm twice daily along with chemotherapy. Blood samples were collected from both groups to get serum sample for IGF-1 before and after trail.
CT was used to assess the radiological response using New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1), IGF-1 was tested using IGF-I ELISA test with No significant cross-reactivity or interference was observed and the Detection Range was 78-5000 pg./mL. To get serum, blood was let to clot at room temperature for at least 30 min and then centrifuged at 1,500 g for 15 min. Serum aliquots were stored at −80 °C until assayed.
The metformin group has slightly longer OS than the control group, but was not statistically significant (5.8; 95% CI 5.4-6) vs. (5.3; 95% CI 4.7- 5.8; p=0.132).as well as PFS was slightly higher in the metformin group than the control group (5.1; 95%CI 5-6) VS. (4.4; 95 %CI 3.425 - 5.421; p=0.179). Partial response was 4% vs. 48%. stable disease 36% vs. 20%, progressive disease was 60% vs. 32% (p=0.002).
There was reduction in IGF-1 in both groups after 3 months of treatment and the reduction of IGF-1 was significantly reduced in metformin group than control group (p-value =0.011)
The mean of PFS in cases with high rate of decline more than 37% in IGF-1 base line was (4.2 vs. 5.3 months) for control group vs. metformin group respectively and it was statistically significant different and the mean of OS in cases with high rate of decline more than 37% in IGF-1 base line was (4.9 vs. 5.7 months) for control group vs. metformin group respectively and it was statistically significant different
Keywords : Metformin -Metastatic breast cancer- IGF-1-OS- PFS.